Question to the Department of Health and Social Care:

To ask Her Majesty’s Government, further to the Written Answer by the Minister of State for Care and Support, Norman Lamb MP, on 26 June (HC Deb, 278W), what progress has been made by the National Institute for Health and Care Excellence’s evaluation committee in the evaluation of eculizumab to treat atypical haemolytic uraemic syndrome.

The National Institute for Health and Care Excellence (NICE) published draft highly specialised technologies guidance on eculizumab for the treatment of atypical haemolytic uraemic syndrome on 4 September. Stakeholders had until 25 September to comment on NICE’s draft recommendations and I understand that it currently expects to issue final guidance to the NHS in January 2015.